Pomerantz Law Firm Investigates Artiva Biotherapeutics Following Program Discontinuation and Fatal Safety Events
Pomerantz LLP has launched an investigation into Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) following the company's announcement to discontinue development of its lead candidate, AlloNK® (AB-101). The decision was driven by updated clinical data showing insufficient durability of response and two fatal Grade 5 safety events during clinical studies for rheumatoid arthritis and autoimmune diseases. In response to the program halt, Artiva announced a massive workforce reduction of approximately 94% and is currently exploring strategic alternatives. These options include a potential merger, asset sale, or complete liquidation of the company. The news caused a significant market reaction, with shares dropping over 30% on the announcement date.
Tickers: $ARTV
Topics: class action lawsuit clinical trial failure layoffs liquidation patient deaths securities fraud investigation